Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 18, 2025 03:00 ET | Source: AdvanCell

AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer

Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastatic castration-resistant prostate cancer...
October 16, 2025 02:00 ET | Source: AdvanCell

AdvanCell appoints experienced biotech and pharma leader, Andrew Kay, as Chair of the Board of Directors

Kay was instrumental in driving the successful development and commercialization of Xofigo®, the first and only approved alpha therapy to date SYDNEY, Australia - October 16, 2025 – AdvanCell, a...
October 12, 2025 18:05 ET | Source: AdvanCell

AdvanCell to present promising clinical trial results of ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for prostate cancer, at ESMO 2025

AdvanCell to present promising clinical trial results of ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for prostate cancer, at ESMO 2025 Results from the Phase 1b dose escalation of the...
September 29, 2025 07:00 ET | Source: AdvanCell

AdvanCell to Highlight the Potential of Pb-212-based Targeted Alpha Therapies for Cancer at EANM’25

Sydney, Australia – September 29, 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, today announced that it will present six...